PDCD1 and neoplasm: Immune checkpoint blockade (ICB), such as anti-programmed cell death-1 (α-PD1) therapy, has achieved remarkable success to fight cancer in the clinic (1, 2), with moderate responses occurring in immunogenic (hot) tumor model (3–5).